ArticleCase reports in oncological medicine2026
Robotic Resection With Hyperthermic Intrathoracic Perfusion Chemotherapy for Thymoma Recurrence.
Article in Case reports in oncological medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Thymoma recurrence with pleural dissemination remains a therapeutic challenge, often requiring multimodal treatment strategies. Cytoreductive surgery combined with hyperthermic intrathoracic chemotherapy (HITHOC) has emerged as a promising approach for selected patients; however, reports using minimally invasive robotic platforms are limited. We present the case of a 41-year-old woman with pleural and lymph node recurrence of type AB thymoma 3 years after robotic extended thymectomy. The patient underwent robotic-assisted cytoreductive surgery, including complete parietal pleurectomy and resection of pleural, pericardial, and subaortic lymph node lesions, followed by HITHOC with cisplatin and doxorubicin. The procedure was performed safely, with no major perioperative complications. The patient was discharged after 7 days and remained disease-free at 2-year follow-up. This case highlights the feasibility, safety, and potential oncological benefits of combining robotic cytoreductive surgery with HITHOC in the management of recurrent thymoma with pleural involvement. This minimally invasive multimodal strategy may represent a valuable option for carefully selected patients, although further studies with larger cohorts and longer follow-up are warranted.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.